Search - Université de Rennes Access content directly

Filter your results

9 Results
Structure: Internal structure identifier : 265275

Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)

Victor De Ledinghen , Claire Laforest , Christophe Hézode , Stanislas Pol , Alain Renault et al.
Hepatology, 2017, 64 (6), pp.1130A--1130A
Journal articles hal-01487921v1

Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort

Sepolene Brichler , Richard Layese , Valérie Bourcier , Carole Cagnot , Patrick Marcellin et al.
Hepatology, 2016, 63 (1 SUPP), pp.898A--899A
Journal articles hal-01414692v1

Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study

Dominique Roulot , Vincent Thibault , Claire Laforest , Hélène Fontaine , Jean-Pierre Bronowicki et al.
European Journal of Gastroenterology & Hepatology, 2018, 30 (3), pp.302-309. ⟨10.1097/MEG.0000000000001035⟩
Journal articles hal-01717743v1

Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study

Xavier Adhoute , Guillaume Penaranda , Jean L. Raoul , Jean F. Blanc , Julien Edeline et al.
European Journal of Gastroenterology & Hepatology, 2016, 28 (4), pp.433--440. ⟨10.1097/MEG.0000000000000558⟩
Journal articles hal-01310454v1

How to guide sorafenib for advanced hepatocellular carcinoma? Usefulness of NIACE score

Xavier Adhoute , Guillaume Penaranda , Jean Luc Raoul , Jean Frederic Blanc , Julien Edeline et al.
Journal of Gastroenterology and Hepatology, 2015, 30, pp.340--340
Journal articles hal-01259235v1

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Marc Bourlière , Jean-Pierre Bronowicki , Victor de Ledinghen , Christophe Hézode , Fabien Zoulim et al.
The Lancet Infectious Diseases, 2015, 15 (4), pp.397-404. ⟨10.1016/S1473-3099(15)70050-2⟩
Journal articles hal-01134440v1

Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program

Christophe Hézode , Victor De Ledinghen , Hélène Fontaine , Fabien Zoulim , Pascal Lebray et al.
Hepatology, 2015, 62, pp.314A--314A. ⟨10.1002/hep.28160⟩
Journal articles hal-01380169v1

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

Christophe Hézode , Hélène Fontaine , Céline Dorival , Dominique Larrey , Fabien Zoulim et al.
Journal of Hepatology, 2013, 59 (3), pp.434 - 441. ⟨10.1016/j.jhep.2013.04.035⟩
Journal articles hal-01708037v1

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy

Farid Kheloufi , Eric Bellissant , Laurent Cotte , Isabelle Poizot-Martin , Sylvie Quaranta et al.
AIDS. Official journal of the international AIDS Society, 2016, 30 (13), pp.2085--2090. ⟨10.1097/QAD.0000000000001143⟩
Journal articles hal-01372823v1